Viriom's Single Pill Influenza Treatment Completes Critical Phase I Clinical Trials
SAN DIEGO, Nov. 20, 2023. Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 21, 2023 Category: Pharmaceuticals Source Type: clinical trials
Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
Leuven, BELGIUM, Boston, MA, US– November 20, 2023– 7:00 am CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company announced today that topline data in its KALAHARI Phase 2, Part B clinical trial for diabetic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
OCEANIC-AF Study Investigating Asundexian Stopped Early Due to Lack of Efficacy
Berlin, November 19, 2023– OCEANIC-AF, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke is being stopped early. This decision is based on the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
CG Pharmaceuticals Announces the Commencement of Phase 2 Study for Metastatic Pancreatic Cancer
ORINDA, Calif., Nov. 17, 2023. CG Pharmaceuticals announces the commencement of Phase 2 study for metastatic pancreatic ductal adenocarcinoma (PDAC) with the recommended Phase 2 dose (RP2D) of ivaltinostat (ClinicalTrials.gov ID NCT05249101).
The... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2023 Category: Pharmaceuticals Source Type: clinical trials
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma
First data from Phase 1 trial show the safety and tolerability of vorasidenib plus KEYTRUDA®... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2023 Category: Pharmaceuticals Source Type: clinical trials
Phase 2 Spring Trial Of LHP588, Treatment For P. Gingivalis-positive Alzheimer's Disease Proceeds
SAN FRANCISCO, Nov. 16, 2023. Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of Alzheimer ' s and other diseases of aging, today announced clearance by the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 16, 2023 Category: Pharmaceuticals Source Type: clinical trials
Astellas Announces Data from ASPIRO Study for AT132 (resamirigene bilparvovec) in X-linked Myotubular Myopathy Published in The Lancet Neurology
TOKYO, Nov. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, " Astellas " ) today announced that The Lancet Neurology published a preliminary data analysis from the ASPIRO trial, evaluating... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 15, 2023 Category: Pharmaceuticals Source Type: clinical trials
Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients
YANTAI, China, Nov. 15, 2023. RemeGen Co., Ltd. ( " RemeGen " or " the Company " ), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 15, 2023 Category: Pharmaceuticals Source Type: clinical trials
Post Hoc Analysis Showed CIMZIA Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
ATLANTA, Nov. 11, 2023. CB, a global biopharmaceutical company, will present a post hoc analysis of the EXXELERATE trial examining the efficacy of CIMZIA (certolizumab pegol) and adalimumab in patients with rheumatoid arthritis (RA) with high... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Bayer Provides Update on Voluntary Withdrawal of Aliqopa (copanlisib)
WHIPPANY, N.J., November 13, 2023--(BUSINESS WIRE)--Bayer today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will work with the FDA on a voluntary withdrawal of the Aliqopa (copanlisib) U.S. New Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Anthos Therapeutics ’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
CAMBRIDGE, Mass., November 12, 2023 (BUSINESS WIRE)– Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences, announced today during a Late-Breaking... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 12, 2023 Category: Pharmaceuticals Source Type: clinical trials
Wegovy (semaglutide) Injection 2.4 mg Cardiovascular Outcomes Data Presented at the American Heart Association Scientific Sessions and Simultaneously Published in the New England Journal of Medicine
PLAINSBORO, N.J., November 11, 2023– Novo Nordisk today announced the full results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly Wegovy® (semaglutide) injection 2.4 mg in adults... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 11, 2023 Category: Pharmaceuticals Source Type: clinical trials
FDA Approves Zepbound for Chronic Weight Management, a New Treatment of Obesity or Overweight with Weight-Related Medical Problems
INDIANAPOLIS, Nov. 8, 2023. The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company ' s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 9, 2023 Category: Pharmaceuticals Source Type: clinical trials
Novartis Data Show Potential of Remibrutinib as an Oral Treatment for Chronic Spontaneous Urticaria Providing Significant Symptom Improvement as Early as Week 2
In pivotal Phase III trials, remibrutinib– a highly selective, oral Bruton’s tyrosine kinase inhibitor– demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo1
Treatment... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 9, 2023 Category: Pharmaceuticals Source Type: clinical trials
